Mustang Bio, Inc.

MBIO

Healthcare|Biotechnology|US

$0.39

+0.00 (+0.15%)

DCF Value

$2.93

Tangible Book / Share

$0.98

Cash / Share

$2.12

About

Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases in the United States. The company develops MB-106, a CD20-targeted chimeric antigen receptor (CAR) T cell therapy which is in Phase I clinical trail for non-hodgkin lymphoma, chronic lymphocytic leukemia, and autoimmune diseases; MB-109, a combination MB-101 and MB-108 as a potential treatment for IL13Ra2+ relapsed or refractory glioblastoma and high-grade astrocytoma; MB-101, an IL13Ra2 CAR T cell program completd Phase I for glioblastoma; and MB-108 which is in Phase I for the treatment of herpes simplex virus-1 oncolytic virus C134. It has a license agreement with city of hope national medical center and nationwide children’s hospital. Mustang Bio, Inc. was incorporated in 2015 and is headquartered in Waltham, Massachusetts.

Stock Price

-68.7%(1Y)

-5.4%

-34.3%

-43.3%

YTD

-59.8%

-67.9%

-99.5%

-100.0%

Pipeline Summary

5 total trials

Phase 1

Phase 2

Phase 3

Phase 4

Active: 2Terminated: 3

Active Trials (2)

Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm

NCT02159495Adult Acute Myeloid Leukemia in Remission

Phase 1Active

Enrollment: 31 participants

A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas

NCT03277729Recurrent B-Cell Non-Hodgkin Lymphoma

Phase 1Phase 2Active

Enrollment: 53 participants

Key Facts

Market Cap$2.7M

Employees4 (-33% YoY)

CEOManuel Litchman

IPO DateAug 22, 2017

Beta2.20

52-Week Range$0.35 – $1.43

Avg Volume31,545

ExchangeNASDAQ

Websitemustangbio.com

Ownership

Float95.7%

Shares Outstanding6.7M

Recent Insider Trades

Litchman Manuel MDTAX W/H

Apr 24, 202619 shares @ $0.75

Fortress Biotech, Inc.AWARD

Jan 2, 2026278,385 shares

Herskowitz NeilSELL

Dec 30, 2025247 shares @ $0.96

Chill Adam J.SELL

Dec 30, 20254 shares @ $0.95

Jin DavidBUY

Dec 30, 2025247 shares @ $0.96

Peers

ABPAbpro Corporation

$1.1M

ACXPAcurx Pharmaceuticals, Inc.

$5.9M

BOLTBolt Biotherapeutics, Inc.

$12.6M

DWTXDogwood Therapeutics, Inc.

$48.9M

EVGNEvogene Ltd.

$2.3M

IMRNImmuron Limited

$5.4M

LYRALyra Therapeutics, Inc.

$337.2K

MRKRMarker Therapeutics, Inc.

$14.9M

Data last updated: Nov 9, 2026, 04:21 AM